Related Experiment Video

Updated: Jun 21, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication

Sho-ichi Yamagishi1, Kazuo Nakamura, Takanori Matsui

  • 1Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp

Pharmacological Research
|August 4, 2009
PubMed

Insights

Advanced glycation end products (AGEs) contribute to cardiovascular disease (CVD) by activating the receptor for AGEs (RAGE). PPARgamma agonists may offer a therapeutic strategy by modulating the AGE-RAGE system in CVD.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Molecular Biology

Background:

  • Non-enzymatic glycation forms advanced glycation end products (AGEs) under physiological aging, oxidative stress, and diabetes.
  • The AGE-RAGE axis is implicated in cardiovascular disease (CVD) pathogenesis, driving oxidative stress, inflammation, and thrombotic responses.
  • AGE-RAGE signaling contributes to vascular injury in both diabetic and non-diabetic conditions.

Purpose of the Study:

  • To review the effects of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists on the AGE-RAGE system.
  • To explore the therapeutic implications of PPARgamma agonists in preventing cardiovascular disease (CVD).

Main Methods:

  • Literature review focusing on the AGE-RAGE axis in CVD.
  • Analysis of studies investigating the role of PPARgamma agonists in modulating AGE-RAGE signaling.
  • Synthesis of evidence regarding the impact of PPARgamma activation on vascular homeostasis.

Main Results:

  • PPARgamma agonists demonstrate potential in influencing the AGE-RAGE pathway.
  • Modulation of the AGE-RAGE system by PPARgamma agonists may mitigate CVD-related cellular responses.
  • Evidence suggests PPARgamma agonists could be a therapeutic target for CVD.

Conclusions:

  • Inhibition of AGE formation, RAGE expression, or downstream signaling are potential CVD therapeutic targets.
  • PPARgamma agonists show promise in modulating the AGE-RAGE system and vascular homeostasis.
  • Further research into PPARgamma agonists could lead to novel CVD prevention strategies.

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Global Regulatory Systems01:28

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...